Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$48.19 USD

48.19
34,745,445

+1.12 (2.38%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $48.34 +0.15 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?

by Kinjel Shah

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

Zacks Equity Research

Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moumi Mondal headshot

Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?

by Moumi Mondal

CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

Ahan Chakraborty headshot

Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?

by Ahan Chakraborty

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Kinjel Shah headshot

Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

by Kinjel Shah

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Zacks Equity Research

NVO Stock up on Plans to Advance Obesity Candidate Amycretin

by Zacks Equity Research

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.

Zacks Equity Research

Company News for Jun 13, 2025

by Zacks Equity Research

Companies In The News Are: ORCL, GOOGL, BA, NVO.

Zacks Equity Research

Why Novo Nordisk (NVO) Outpaced the Stock Market Today

by Zacks Equity Research

Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.

Zacks Equity Research

NVO Stock Gains After Parvus Asset Management Builds Stake

by Zacks Equity Research

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.

Kinjel Shah headshot

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

by Kinjel Shah

LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.

Zacks Equity Research

The Zacks Analyst Blog Highlights Oracle, Novo Nordisk, Linde, NVE and CPS Technologies

by Zacks Equity Research

Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.

Kinjel Shah headshot

Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?

by Kinjel Shah

PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.

Mark Vickery headshot

Top Research Reports for Oracle, Novo Nordisk & Linde

by Mark Vickery

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

Zacks Equity Research

Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?

by Zacks Equity Research

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Zacks Equity Research

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

by Zacks Equity Research

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

Zacks Equity Research

Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Sanghamitra Saha headshot

Weight Loss Drug ETF (THNR) Hits New 52-Week High

by Sanghamitra Saha

THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?

Kinjel Shah headshot

AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?

by Kinjel Shah

ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.

Zacks Equity Research

Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer

by Zacks Equity Research

LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.

Kinjel Shah headshot

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?

by Kinjel Shah

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Sundeep Ganoria headshot

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

by Sundeep Ganoria

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Zacks Equity Research

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

by Zacks Equity Research

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Zacks Equity Research

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.